Shortly after winning a stay on a COVID-19 vaccine patent lawsuit brought by Moderna, Pfizer and its German partner BioNTech are being dragged into another round of mRNA litigation by GSK. GSK on ...
Matthew Herper covers medical innovation — both its promise and its perils. Pfizer and BioNTech said Friday that their combined mRNA vaccine candidate against influenza and Covid-19 showed a lower ...
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate ...
BioNTech (BNTX) has reached settlement agreements with the U.S. National Institutes of Health (NIH) and the University of Pennsylvania over royalties tied to its COVID-19 vaccine, resolving disputes ...
It seeks an overnight block trade of about 4.55 million American depositary receipts, priced between $108 and $111.70 apiece, according to a Bloomberg report. The sale could fetch roughly $508 million ...
After nearly two years of legal back and forth, Pfizer and its German partner BioNTech have won a brief reprieve in their patent fight against mRNA rival Moderna. In a docket entry dated Friday, ...
BioNTech (BNTX) ADRs lost ~5% in the premarket on Thursday after Bloomberg News reported that Pfizer (PFE) is planning to sell its remaining stake in its partner, which helped the U.S. pharma giant to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback